Continual reassessment method with multiple toxicity constraints

Biostatistics

Volumn 12, Issue 2, 2011, Pages 386-398

  Lee, Shing M ^a   Cheng, Bin ^a   Cheung, Ying Kuen ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Design calibration; Dose finding cancer trials; Toxicity grades and types

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PYRAZINE DERIVATIVE; VINCRISTINE;

ALGORITHM; ARTICLE; CALIBRATION; CHEMICALLY INDUCED DISORDER; COMPUTER SIMULATION; DRUG TOXICITY; EPIDEMIOLOGY; HUMAN; MAXIMUM TOLERATED DOSE; METHODOLOGY; NEOPLASM; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PROBABILITY; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; THROMBOCYTOPENIA; TOXICITY AND INTOXICATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CALIBRATION; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG TOXICITY; EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; LYMPHOMA, NON-HODGKIN; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; NEOPLASMS; NEUROTOXICITY SYNDROMES; PREDNISOLONE; PROBABILITY; PYRAZINES; STATISTICAL DISTRIBUTIONS; THROMBOCYTOPENIA; VINCRISTINE;

EID: 79953141091     PISSN: 14654644     EISSN: 14684357     Source Type: Journal    
DOI: 10.1093/biostatistics/kxq062     Document Type: Article

References (20)

1. BEKELE, B. N., LI, Y. AND JI, Y. (2009). Risk-group-specifc dose fnding based on an average toxicity score. Biometrics 66, 541-548.
2. BEKELE, B. N. AND THALL, P. (2004). Dose-fnding based on multiple toxicities in a soft tissue sarcoma trial. Journal of the American Statistical Association 99, 26-35. (Pubitemid 38545191)
3. CHEUNG, Y. K. (2002). On the use of non-parametric curves in phase I trials with low toxicity tolerance. Biometrics 58, 237-240. (Pubitemid 34194510)
4. CHEUNG, Y. K. (2005). Coherence principles in dose-fnding studies. Biometrika 92, 863-873.
5. CHEUNG, Y. K. (2007). Sequential implementation of stepwise procedures for identifying the maximum tolerated dose. Journal of the American Statistical Association 102, 1448-1461.
6. CHEUNG, Y. K. AND CHAPPELL, R. (2002). A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 58, 671-674. (Pubitemid 35001486)
7. CHEUNG, Y. K. AND ELKIND, M. S. V. (2010). Stochastic approximation with virtual observations for dose-fnding on discrete levels. Biometrika 97, 109-121.
8. DURHAM, S. D., FLOURNOY, N. AND ROSENBERGER, W. (1997). A random walk rule for phase I clinical trials. Biometrics 53, 745-760. (Pubitemid 27262236)
9. FLEISS, J., LEVIN, B. AND PAIK, M. C. (2003). Statistical Methods for Rates and Proportions. New York: Wiley-Interscience.
10. GOODMAN, S. N., ZAHURAK, M. L. AND PIANTADOSI, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 14, 1149-1161.
11. IVANOVA, A. AND KIM, S. H. (2009). Dose fnding for continuous and ordinal outcomes with a monotone objective function: a unifed approach. Biometrics 65, 247-255.
12. JI, Y., LI, Y. AND BEKELE, N. (2007). Dose-fnding in phase I clinical trials based on toxicity probability intervals. Clinical Trials 4, 235-244.
13. LEE, S. M. AND CHEUNG, Y. K. (2009). Model calibration in the continual reassessment method. Clinical Trials 6, 227-238.
14. LEE, S. M., HERSHMAN, D., MARTIN, P., LEONARD, K. AND CHEUNG, Y. K. (2009). Validation of toxicity burden score for use in phase I clinical trials. Journal of Clinical Oncology 27 (Suppl.), 15s (abstr. 2514).
15. LEONARD, J. P., FURMAN, R. R., CHEUNG, Y. K. K., FELDMAN, E. J., CHO, H. J., VOSE, J. M., NICHOLS, G., GLYNN, P. W., JOYCE, M. A., KETAS, J. and others (2005). Phase I/II trial of bortezomib plus CHOP-Rituximab in diffuse large B cell (DLBCL) and mantle cell lymphona (MCL): phase I results. Blood 106, 147a (abstr. 491).
16. LUNN, D. J., THOMAS, A., BEST, N. AND SPIEGELHALTER, D. (2000). WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 10, 325-337.
17. NATIONAL CANCER INSTITUTE (2003). Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. Bethesda: National Cancer Institute. http://ctep.cancer.gov/forms/CTCAEv3.pdf.
18. O'QUIGLEY, J., PEPE, M. AND FISHER, L. (1990). Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46, 33-48. (Pubitemid 20245604)
19. SIMON, R., FREIDLIN, B., RUBINSTEIN, L., ARBUCK, S. G., COLLINS, J. AND CHRISTIAN, M. C. (1997). Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89, 1138-1147. (Pubitemid 27337928)
20. YUAN, Z., CHAPPELL, R. AND BAILEY, H. (2007). The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach. Biometrics 63, 173-179.